Literature DB >> 25528729

Structural modeling and docking studies of ribose 5-phosphate isomerase from Leishmania major and Homo sapiens: a comparative analysis for Leishmaniasis treatment.

Priscila V S Z Capriles1, Luiz Phillippe R Baptista2, Isabella A Guedes3, Ana Carolina R Guimarães4, Fabio L Custódio3, Marcelo Alves-Ferreira5, Laurent E Dardenne6.   

Abstract

Leishmaniases are caused by protozoa of the genus Leishmania and are considered the second-highest cause of death worldwide by parasitic infection. The drugs available for treatment in humans are becoming ineffective mainly due to parasite resistance; therefore, it is extremely important to develop a new chemotherapy against these parasites. A crucial aspect of drug design development is the identification and characterization of novel molecular targets. In this work, through an in silico comparative analysis between the genomes of Leishmania major and Homo sapiens, the enzyme ribose 5-phosphate isomerase (R5PI) was indicated as a promising molecular target. R5PI is an important enzyme that acts in the pentose phosphate pathway and catalyzes the interconversion of d-ribose-5-phosphate (R5P) and d-ribulose-5-phosphate (5RP). R5PI activity is found in two analogous groups of enzymes called RpiA (found in H. sapiens) and RpiB (found in L. major). Here, we present the first report of the three-dimensional (3D) structures and active sites of RpiB from L. major (LmRpiB) and RpiA from H. sapiens (HsRpiA). Three-dimensional models were constructed by applying a hybrid methodology that combines comparative and ab initio modeling techniques, and the active site was characterized based on docking studies of the substrates R5P (furanose and ring-opened forms) and 5RP. Our comparative analyses show that these proteins are structural analogs and that distinct residues participate in the interconversion of R5P and 5RP. We propose two distinct reaction mechanisms for the reversible isomerization of R5P to 5RP, which is catalyzed by LmRpiB and HsRpiA. We expect that the present results will be important in guiding future molecular modeling studies to develop new drugs that are specially designed to inhibit the parasitic form of the enzyme without significant effects on the human analog.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Homo sapiens; Leishmania major; Leishmaniasis treatment; Protein structure prediction; Protein–ligand docking; Ribose 5-phosphate isomerase

Mesh:

Substances:

Year:  2014        PMID: 25528729     DOI: 10.1016/j.jmgm.2014.11.002

Source DB:  PubMed          Journal:  J Mol Graph Model        ISSN: 1093-3263            Impact factor:   2.518


  6 in total

1.  Computer-aided discovery of two novel chalcone-like compounds active and selective against Leishmania infantum.

Authors:  Marcelo N Gomes; Laura M Alcântara; Bruno J Neves; Cleber C Melo-Filho; Lucio H Freitas-Junior; Carolina B Moraes; Rui Ma; Scott G Franzblau; Eugene Muratov; Carolina Horta Andrade
Journal:  Bioorg Med Chem Lett       Date:  2017-04-04       Impact factor: 2.823

2.  Toward Chemical Validation of Leishmania infantum Ribose 5-Phosphate Isomerase as a Drug Target.

Authors:  Emily A Dickie; Céline Ronin; Mónica Sá; Fabrice Ciesielski; Nathalie Trouche; Joana Tavares; Nuno Santarem; Louise L Major; Iain K Pemberton; Jane MacDougall; Terry K Smith; Anabela Cordeiro-da-Silva; Paola Ciapetti
Journal:  Antimicrob Agents Chemother       Date:  2021-06-17       Impact factor: 5.191

3.  A Computational Methodology to Overcome the Challenges Associated With the Search for Specific Enzyme Targets to Develop Drugs Against Leishmania major.

Authors:  Larissa Catharina; Carlyle Ribeiro Lima; Alexander Franca; Ana Carolina Ramos Guimarães; Marcelo Alves-Ferreira; Pierre Tuffery; Philippe Derreumaux; Nicolas Carels
Journal:  Bioinform Biol Insights       Date:  2017-06-12

4.  Structure, kinetic characterization and subcellular localization of the two ribulose 5-phosphate epimerase isoenzymes from Trypanosoma cruzi.

Authors:  Soledad Natalia Gonzalez; Wanda Mariela Valsecchi; Dante Maugeri; José María Delfino; Juan José Cazzulo
Journal:  PLoS One       Date:  2017-02-16       Impact factor: 3.240

5.  Analysis of a novel class A β-lactamase OKP-B-6 of Klebsiella quasipneumoniae: structural characterisation and interaction with commercially available drugs.

Authors:  Reinaldo Bellini; Isabella Alvim Guedes; Luciane Prioli Ciapina; Ana Tereza Ribeiro de Vasconcelos; Laurent Emmanuel Dardenne; Marisa Fabiana Nicolás
Journal:  Mem Inst Oswaldo Cruz       Date:  2022-09-23       Impact factor: 2.747

6.  Mutational and Structural Analysis of Conserved Residues in Ribose-5-Phosphate Isomerase B from Leishmania donovani: Role in Substrate Recognition and Conformational Stability.

Authors:  Preet Kamal Kaur; Neha Tripathi; Jayesh Desale; Soumya Neelagiri; Shailendra Yadav; Prasad V Bharatam; Sushma Singh
Journal:  PLoS One       Date:  2016-03-08       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.